LINC01017: A Potential Drug Target and Biomarker (G102467075)

Target Name: LINC01017

NCBI ID: G102467075

LINC01017

Other Name(s): Long intergenic non-protein coding RNA 1017 | long intergenic non-protein coding RNA 1017

LINC01017: A Potential Drug Target and Biomarker

LINC01017 is a non-coding RNA (ncRNA) molecule that has been identified by bioinformatics analysis as belonging to the LINC (Long non-coding RNAs) family. This family of RNA molecules has been shown to play important roles in various cellular processes, including gene regulation, RNA homeostasis, and cell signaling. As such, LINC01017 is a promising candidate for further investigation as a drug target or biomarker.

Drug Target Potential

The drug discovery process typically begins with the identification of potential drug targets. In the case of LINC01017, its potential as a drug target is based on its involvement in cellular signaling pathways. LINC01017 has been shown to play a role in the regulation of mitochondrial function and to control the expression of genes involved in cell signaling pathways, including NF-kappa signaling.

NF-kappa signaling is a well-established signaling pathway that plays a central role in cellular development, tissue repair, and regeneration. It is involved in the regulation of cell proliferation, differentiation, and survival, and is often disrupted in various diseases, including cancer. Therefore, targeting LINC01017 with drugs that can modulate NF-kappa signaling pathway could be a promising strategy for the development of new treatments for a variety of diseases.

Biomarker Potential

In addition to its potential as a drug target, LINC01017 may also be a valuable biomarker for the diagnosis and prognosis of various diseases. Its involvement in NF-kappa signaling has been shown to be involved in the regulation of cellular processes that are important for disease progression, such as cancer cell growth, angiogenesis, and immune cell function.

Therefore, LINC01017 may be a useful biomarker for the diagnosis and prognosis of diseases that are characterized by uncontrolled NF-kappa signaling, such as cancer, cardiovascular disease, and neurodegenerative diseases. Additionally, its expression levels may be relevant to the efficacy of drugs that target NF-kappa signaling pathways, providing a potential target for biomarker-based diagnostic tests and personalized medicine.

Conclusion

In conclusion, LINC01017 is a promising candidate for further investigation as a drug target and biomarker. Its involvement in NF-kappa signaling and its potential as a regulator of cellular processes important for disease progression make it an attractive target for drug development. Further studies are needed to determine its functional role in cellular processes and to develop effective strategies for its targeting with drugs or as a biomarker for disease diagnosis and prognosis.

Protein Name: Long Intergenic Non-protein Coding RNA 1017

The "LINC01017 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01017 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets